# Study of LW231 in Participants With Chronic Hepatitis B

> **NCT07179575** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Longwood Biopharmaceuticals Co., Ltd.** · enrollment: 270 (estimated)

## Conditions studied

- Chronic HBV Infection

## Interventions

- **DRUG:** LW231
- **DRUG:** LW231 placebo

## Key facts

- **NCT ID:** NCT07179575
- **Lead sponsor:** Shanghai Longwood Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2027-03
- **Final completion:** 2027-11
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179575, "Study of LW231 in Participants With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07179575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*